<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>55</volume><submitter>Biancari F</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The evidence of the long-term advantages of transcatheter aortic valve replacement (TAVR) over surgical aortic valve replacement (SAVR) for aortic stenosis (AS) remains scarce.&lt;h4>Methods&lt;/h4>Patients with EuroSCORE II &lt; 4 % who underwent TAVR or SAVR for AS from the prospective observational OBSERVANT study were included in this analysis. Ten-year survival was the primary outcome of this analysis. Secondary outcome was repeat procedure on the aortic valve prosthesis.&lt;h4>Results&lt;/h4>Propensity score matching resulted in 355 matched pairs of patients who underwent TAVR or SAVR. The mean age of SAVR patients was 80.0 ± 5.1 years and that of TAVR patients 80.1 ± 6.4 years (p = 0.81) and the mean EuroSCORE II was 2.5 ± 0.8 % and 2.6 ± 0.8 % (p = 0.60), respectively. Thirty-d</pubmed_abstract><journal>International journal of cardiology. Heart &amp; vasculature</journal><pagination>101545</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11567919</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ten-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients: The OBSERVANT study.</pubmed_title><pmcid>PMC11567919</pmcid><pubmed_authors>Baglio G</pubmed_authors><pubmed_authors>Badoni G</pubmed_authors><pubmed_authors>Biancari F</pubmed_authors><pubmed_authors>Polvani G</pubmed_authors><pubmed_authors>Rosato S</pubmed_authors><pubmed_authors>D'Errigo P</pubmed_authors><pubmed_authors>Costa G</pubmed_authors><pubmed_authors>Barbanti M</pubmed_authors><pubmed_authors>Tamburino C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ten-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients: The OBSERVANT study.</name><description>&lt;h4>Background&lt;/h4>The evidence of the long-term advantages of transcatheter aortic valve replacement (TAVR) over surgical aortic valve replacement (SAVR) for aortic stenosis (AS) remains scarce.&lt;h4>Methods&lt;/h4>Patients with EuroSCORE II &lt; 4 % who underwent TAVR or SAVR for AS from the prospective observational OBSERVANT study were included in this analysis. Ten-year survival was the primary outcome of this analysis. Secondary outcome was repeat procedure on the aortic valve prosthesis.&lt;h4>Results&lt;/h4>Propensity score matching resulted in 355 matched pairs of patients who underwent TAVR or SAVR. The mean age of SAVR patients was 80.0 ± 5.1 years and that of TAVR patients 80.1 ± 6.4 years (p = 0.81) and the mean EuroSCORE II was 2.5 ± 0.8 % and 2.6 ± 0.8 % (p = 0.60), respectively. Thirty-d</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-03T23:23:42.491Z</modification><creation>2025-04-03T23:23:42.491Z</creation></dates><accession>S-EPMC11567919</accession><cross_references><pubmed>39555490</pubmed><doi>10.1016/j.ijcha.2024.101545</doi></cross_references></HashMap>